Category Archives: Global News Feed

Not for distribution to U.S. news wire services or dissemination in the United States

Originally posted here:
Kane Biotech Clarifies Terms of Credit Facility

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the original post:
Mendus AB: Mendus announces request for conversion of convertible bonds by Negma Group

BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- February 23, 2023 (GLOBENEWSWIRE) – binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, announced today that Jeff Luber, Chief Executive Officer, will present at the BioCapital Europe 2023, a life sciences investment conference taking place on March 9, 2023, in Amsterdam, the Netherlands. The presentation will feature the binx io, the first ever FDA-cleared, CLIA-waived, point-of-care chlamydia and gonorrhea test for males and females, providing central lab performance results in about thirty minutes. Additional conference and presentation details are as follows:

Go here to read the rest:
binx health to Present at the Upcoming BioCapital Europe 2023 Conference

FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

See the article here:
Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection

– Generated Record Quarterly and Full-Year Net Revenue of $129.6 and $463.9 Million –

Link:
Collegium Reports Fourth Quarter and Full-Year 2022 Financial Results

Recently received U.S. FDA accelerated approval of FILSPARI™ (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy (IgAN)

Here is the original post:
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Data to be Presented in Five Poster Presentations at the 2023 American Academy of Allergy, Asthma and Immunology Annual Meeting

Read the original here:
ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

Key 2022 and post-period events

Originally posted here:
Galapagos announces full year 2022 results and outlook for 2023

LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended December 31, 2022 (the "Form 10-Q"), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Company received notices from Nasdaq indicating that as a result of not having timely filed its Annual Report on Form 10-K for the period ended June 30, 2022 (the "Form 10-K") and its Quarterly Report on Form 10-Q for the period ended September 30, 2022, the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1).

Read more from the original source:
Enochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose –

Read the original post:
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results